Center-Authored Papers

Filters: Author is Yu, Evan Y  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Alva A, Nordquist L, Daignault S, George S, Ramos J, Albany C, Isharwal S, McDonald M, Campbell G, Danchaivijitr P et al..  2016.  Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.. The Prostate. Abstract
Antonarakis ES, Kibel AS, Yu EY, Karsh LI, Elfiky A, Shore ND, Vogelzang NJ, Corman JM, Millard FE, Maher JC et al..  2016.  Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically-Recurrent Prostate Cancer: A Phase II Randomized Trial.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG et al..  2013.  A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.. Cancer chemotherapy and pharmacology. Abstract
Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB et al..  2013.  Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.. The lancet oncology. 14(13):1307-16. Abstract
Armstrong AJ, Halabi S, Healy P, Alumkal JJ, Winters C, Kephart J, Bitting RL, Hobbs C, Soleau CF, Beer TM et al..  2017.  Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.. European journal of cancer (Oxford, England : 1990). Abstract
B
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL et al..  2016.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.. Lancet (London, England). Abstract
Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC, Chowdhury S, Niegisch G et al..  2017.  Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.. Acta oncologica (Stockholm, Sweden). :1-7. Abstract
C
Cheng HH, Lin DW, Yu EY.  2012.  Advanced clinical States in prostate cancer.. The Urologic clinics of North America. 39(4):561-71. Abstract
Cheng HH, Klemfuss N, Montgomery B, Higano CS, Schweizer MT, Mostaghel EA, McFerrin LG, Yu EY, Nelson PS, Pritchard CC.  2016.  A pilot study of clinical targeted next generation sequencing for prostate cancer: Consequences for treatment and genetic counseling.. The Prostate. Abstract
Cheng HH, Soleau C, Yu EY.  2015.  Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy.. Journal of hematology & oncology. 8(1):51. Abstract
Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, Cheng HH, Arroyo JD, Meredith EK, Gallichotte EN et al..  2014.  Quantitative and stoichiometric analysis of the microRNA content of exosomes.. Proceedings of the National Academy of Sciences of the United States of America. 111(41):14888-93. Abstract
Cowan AJ, Inoue Y, Yu EY.  2015.  Delayed antiandrogen withdrawal syndrome after discontinuation of bicalutamide.. Clinical genitourinary cancer. 13(1):e51-3.
Crawford DE, Petrylak DP, Shore N, Saad F, Slovin SF, Vogelzang NJ, Keane TE, Koo PJ, Gomella LG, O'Sullivan JM et al..  2017.  The Role of Therapeutic Layering in Optimizing Treatment for Patients with Castration-Resistant Prostate Cancer (RADAR II).. Urology. Abstract
Crawford DE, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger RE, Keane TE, Sieber P et al..  2014.  Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer.. Urology. Abstract
G
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong Y-N, Yu EY, Powles T, Moshier EL, Ladoire S et al..  2015.  Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.. Cancer. Abstract
H
Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, Macvicar GR, Levine EG, Srinivas S, Twardowski P et al..  2014.  A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.. Cancer. Abstract
I
Izard JP, Gore JL, Mostaghel EA, Wright JL, Yu EY.  2015.  Persistent, Unexplained Leukocytosis Is a Paraneoplastic Syndrome Associated With a Poor Prognosis in Patients With Urothelial Carcinoma.. Clinical genitourinary cancer. Abstract
J
James AC, Lee FC, Izard JP, Harris WP, Cheng HH, Zhao S, Gore JL, Lin DW, Porter MP, Yu EY et al..  2014.  Role of Maximal Endoscopic Resection Before Cystectomy for Invasive Urothelial Bladder Cancer.. Clinical genitourinary cancer. Abstract
K
Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T et al..  2016.  Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.. Nature medicine. Abstract
L
Lee FC, Harris W, Cheng HH, Shenoi J, Zhao S, Wang J, Champion T, Izard J, Gore JL, Porter M et al..  2013.  Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer.. Advances in urology. 2013:317190. Abstract
M
Mainwaring P, Yu EY, Londhe A, Van Poppel H, Rathkopf DE, Smith MR, Souza P, Griffin TW, Ryan CJ, Investigators SCOU-AA-302.  2014.  Association of alkaline phosphatase with clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302. Bju International. 113:21-21. Abstract
Mossanen M, Lee F, Cheng H, Harris W, Shenoi J, Zhao S, Wang J, Champion T, Izard J, Gore JL et al..  2013.  Nonresponse to Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Cell Carcinoma of the Bladder.. Clinical genitourinary cancer. Abstract
N
Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong Y-N, Harshman LC, Alva A, Sternberg CN, Bamias A et al..  2017.  Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.. European urology focus. Abstract
Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN et al..  2016.  Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).. European urology. Abstract
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong Y-N, Viterbo R, Sonpavde G, Harshman LC, Crabb S et al..  2017.  Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.. European urology focus. Abstract